{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anastrozole+%281+mg%2Fday%29&page=3", "query": { "intervention": "anastrozole (1 mg/day)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 93, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anastrozole+%281+mg%2Fday%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anastrozole+%281+mg%2Fday%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T01:09:05.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Toremifine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2014-12-18", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 8, "location_summary": "Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02291913" }, { "nct_id": "NCT00555477", "title": "Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 69, "start_date": "2007-08", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-06-19", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00555477" }, { "nct_id": "NCT03874325", "title": "Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Anastrozole 1mg", "type": "DRUG" }, { "name": "Letrozole 2.5mg", "type": "DRUG" }, { "name": "Exemestane 25 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2019-04-26", "completion_date": "2021-01-06", "has_results": true, "last_update_posted_date": "2022-05-31", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03874325" }, { "nct_id": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "17B-estradiol", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2016-03-11", "completion_date": "2024-07-05", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 3, "location_summary": "Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire", "locations": [ { "city": "Springfield", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188745" }, { "nct_id": "NCT00077025", "title": "Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gefitinib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 174, "start_date": "2004-01", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 16, "location_summary": "La Jolla, California • San Diego, California • Orlando, Florida + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077025" }, { "nct_id": "NCT03304080", "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Diseases" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2017-12-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 5, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03304080" }, { "nct_id": "NCT04886531", "title": "Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive Breast Cancer", "ER Positive Breast Cancer", "PR-Positive Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Letrozole (L) or Anastrozole (A)", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ruth O'Regan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-07-21", "completion_date": "2027-12-21", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 4, "location_summary": "Chicago, Illinois • Rochester, New York • Hershey, Pennsylvania + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886531" }, { "nct_id": "NCT00248170", "title": "Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "33 Years", "maximum_age": "96 Years", "sex": "FEMALE", "summary": "33 Years to 96 Years · Female only" }, "enrollment_count": 4172, "start_date": "2005-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "New London", "state": "Connecticut" }, { "city": "Fort Meyers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248170" }, { "nct_id": "NCT03099174", "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Breast Neoplasms" ], "interventions": [ { "name": "Xentuzumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-05-04", "completion_date": "2024-05-16", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 6, "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099174" }, { "nct_id": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priscilla McAuliffe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 201, "start_date": "2015-09-30", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-09T01:09:05.075Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206984" } ] }